Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAO: Exenatide for Antipsychotic-associated Obesity
NCT01794429Phase 3Completed
- Start
- Feb 2013
- Primary completion
- Jun 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Exenatide with Placebo (2 arms). Primary endpoint: Weight loss at 3 months. Started Feb 2013; status: completed.
02
Drugs
exenatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT01794429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01794429.